about us.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
Pipeline
Seralutinib (GB002) –
Inhaled PDGFR, CSF1R, c-KIT inhibitor
Pulmonary Arterial Hypertension
Phase 2 ongoingGB5121 – Primary CNS Lymphoma
Oral CNS-Penetrant BTK Inhibitor
Phase 1 ongoingGB7208 – Multiple Sclerosis
Oral CNS-Penetrant BTK Inhibitor
Preclinical ProgramsDiscovery Programs
Multiple Preclinical Programs
Seralutinib (GB002) –
Pulmonary Arterial HypertensionGB5121 – Primary CNS Lymphoma
GB7208 – Multiple Sclerosis
*Targets to be disclosed
scroll